The Schistosomiasis Vaccine Initiative was launched in 2008 through funding from Mr. Morton Hyman and the Blavatnik Family Foundation. In collaboration with researchers at James Cook University and The George Washington University, a promising antigen, Sm-TSP-2, was selected for development.


November 2012
Initiation of Good Laboratory Practice (GLP) toxicology study.
January to October 2012
Release of clinical lots and initiation of stability program.
December 2011
Current Good Manufacturing Practice (cGMP) manufacture of Sm-TSP-2 completed.
January 2009
Development of the manufacturing process for Sm-TSP-2 schistosomiasis vaccine begins.
March 2008
Sabin Vaccine Institute acquires the exclusive license to the intellectual property for Sm-TSP-2 antigen from the Queensland Institute of Medical Research. Patent applications are filed in the United States, Brazil, Australia and India.
November 2007
Sabin Vaccine Development receives its initial funding from private donors to establish SVI and develop the Sm-TSP-2 schistosomiasis vaccine.